CASP1 and triple-negative breast carcinoma: In triple-negative breast cancer, cisplatin activated MEG3/NLRP3/CASP-1 pathway to induce cell pyroptosis, which suggested that MEG3 was involved in the pyroptosis pathway of cisplatin therapy [23].